Bristol Myers Squibb Data at ASH 2022 Highlight Innovative remedial Platforms Across a Range of Blood conditions
PRINCETON,N.J.–( BUSINESS WIRE)– Bristol Myers Squibb( NYSE BMY) blazoned the donation of exploration across its hematology portfolio at the 64th American Society of Hematology( ASH) Annual Meeting and Exposition, which will take place in New Orleans, Louisiana, and nearly, from December 10 to 13, 2022. Data from further than 100 company- patronized studies will be featured, including 34 oral donations, pressing the range of modalities, targets and exploration platforms the company is advancing and showcasing our commitment to scientific progress across hematologic conditions.
“ Our presence at ASH underscores the transformational eventuality of our different channel, poised to deliver the coming surge of advances in hematology, ” said Samit Hirawat,M.D., administrative vice chairman, principal medical officer, Global Drug Development, Bristol Myers Squibb. “ These instigative data, gauging a variety of modalities and targets, demonstrate significant progress toward our pretensions of perfecting long- term issues across patient populations and chancing results in important areas of remaining need. ”
crucial data being presented by Bristol Myers Squibb and its mates at the 2022 ASH Annual Meeting and Exposition include
Cell Remedy
streamlined data including longer- term follow up from the primary analysis of the Phase 3 transfigure study assessing Breyanzi ®( lisocabtagene maraleucel) versus the standard of care as a alternate- line treatment in regressed or refractory large B- cell carcinoma( LBCL)
streamlined data from the primary analysis of the Phase 2 OUTREACH study assessing Breyanzi as a third- line plus treatment in regressed or refractory LBCL in the community setting
Safety and efficacity results of the match- acclimated circular comparison of the TRANSFORM versus ZUMA- 7 studies assessing Breyanzi versusaxicabtagene ciloleucelin the alternate- line setting in regressed or refractory LBCL
Two first exposures of results from cohorts 2a and 2c of the Phase 2 KarMMa- 2 trial assessing Abecma in high- threat multiple myeloma
First exposure of primary Phase 1 results for GPRC5D fantastic antigen receptor( Auto) T cell remedy in cases with regressed refractory( R/ R) multiple myeloma, including cases preliminarily treated with a B- cell development antigen( BCMA)- directed Auto T cell remedy
Hematology
Multiple analyses of Reblozyl ®( luspatercept- aamt), including overall survival data from the Phase 3 Semifinalist study in lower- threat myelodysplastic runs and real- world, longer- term results from the Phase 2 BEYOND study in beta thalassemia
Multiple analyses of Inrebic ®( fedratinib), including the primary analysis of safety and efficacity from the Phase 3b FREEDOM trial in intermediate- or high- threat myelofibrosis
Longitudinal analyses of acute myeloid leukemia gene mutations with Onureg ®( azacitidine tablets) from the Phase 3 QUAZAR ® AML- 001 study
Beforehand Pipeline
First exposure of primary results from the cure escalation and expansion factors of the Phase 1 CC- 93269 MM- 001 study, assessing subcutaneous bispecific T cell engager alnuctamab in heavily pretreated multiple myeloma
First results from cure expansion cohort of the CC- 92480 Phase1/2 MM- 001 study, assessing CELMoDTM agent mezigdomide with dexamethasone in cases with R/ R multiple myeloma
Results frompost-BCMA cohort of the CC- 220 Phase1/2 MM- 001 study, assessing CELMoD agent iberdomide with dexamethasone in cases with R/ R multiple myeloma preliminarily treated with a BCMA- directed remedy
First results from a Phase1/2 study assessing BMS- 986158, a potent Bromodomain and Extraterminal( BET) asset, as monotherapy and in combination with ruxolitinib or Inrebic in intermediate- or high- threat myelofibrosis
Source link: https://news.bms.com/
